Remedium Capital Partners, LLC holds a concentrated book of 6 reported positions worth $451.6M as of Q2 2026 (disclosed Aug 7, 2026, a ~38-day 13F lag). This quarter they opened Crescent Biopharma Inc. Their largest long position is Oruka Therapeutics Inc at 33% of the reported non-option book. Cloning the disclosed picks since 2026 would be +135% (+337.5%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 30.3 points over this window.
Growth of $10,000 cloning Remedium Capital Partners, LLC's disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~38 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
100% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices (an exit at the prior quarter-end), no cost basis
Other tracked managers holding the same core names as Remedium Capital Partners, LLC
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| Venrock Adviser, LLC | 6 / 6 | $2.0B |
| Fairmount Funds Management LLC | 5 / 6 | $769.5M |
| Avidity Partners Management LP | 2 / 6 | $110.2M |
| Paradigm Biocapital Advisors LP | 4 / 6 | $817.8M |
| FCPM III Services B.V. | 2 / 6 | $93.7M |
| Affinity Asset Advisors, LLC | 5 / 6 | $217.8M |
| Perceptive Advisors LLC | 5 / 6 | $720.7M |
| Tang Capital Management LLC | 2 / 6 | $188.9M |
Ranked by the share of each fund's own book sitting in the names it shares with Remedium Capital Partners, LLC: only funds sharing at least a tenth of the book qualify. Index giants, bank custody books and market makers are excluded. They hold everything, so their overlap says nothing.
Bars show each position's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Oruka Therapeutics Inc COM | $149.0M | 1.57M | 33.0% | —Held | |
| 2 | Spyre Therapeutics Inc COM | $130.0M | 1.46M | 28.8% | ▲+0.5% Added · +8K sh | |
| 3 | Apogee Therapeutics Inc COM | $77.9M | 586.7K | 17.2% | ▲+0.5% Added · +3K sh | |
| 4 | Damora Therapeutics Inc COM | $53.2M | 2.05M | 11.8% | —Held | |
| 5 | Jade Biosciences Inc COM | $35.1M | 1.58M | 7.8% | —Held | |
| 6 | Crescent Biopharma Inc COM | $6.5M | 361.3K | 1.4% | ▲New New position |
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/2104501/holdings"
Use Arkolith to show Remedium Capital Partners, LLC's latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
Reported 13F total per quarter. Raw filing totals can include option notional.
| Quarter | As of | Filed | Lag | Positions | Value | Form |
|---|---|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | Aug 7, 2026 | 38d | 6 | $451.6M | 13F-HR |
| Q1 2026 | Mar 31, 2026 | May 19, 2026 | 49d | 6 | $281.2M | 13F-HR/A |
| Q4 2025 | Dec 31, 2025 | Feb 12, 2026 | 43d | 6 | $170.2M | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. Book totals and portfolio weights cover reported non-option positions, which can include notes and warrants. Disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.